ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Authors
Passaro, AAddeo, A
Von Garnier, C
Blackhall, Fiona H
Planchard, D
Felip, E
Dziadziuszko, R
de Marinis, F
Reck, M
Bouchaab, H
Peters, S
Affiliation
Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy Antonio.Passaro@ieo.it.Issue Date
2020
Metadata
Show full item recordAbstract
The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care.This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)-defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale.The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment.These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients.As the situation is rapidly evolving, practical actions are required to guarantee the best patients' treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers. Keywords: COVID19; SARS-CoV-2; lung cancer.Citation
Passaro A, Addeo A, Von Garnier C, Blackhall F, Planchard D, Felip E, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open. 2020;5(Suppl 3).Journal
ESMO OpenDOI
10.1136/esmoopen-2020-000820PubMed ID
32581069Additional Links
https://dx.doi.org/10.1136/esmoopen-2020-000820Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/esmoopen-2020-000820
Scopus Count
Collections
Related articles
- Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic.
- Authors: Blais N, Bouchard M, Chinas M, Lizotte H, Morneau M, Spicer J, Martel S
- Issue date: 2020 Jun
- ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.
- Authors: Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F
- Issue date: 2020 May
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
- Authors: de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G
- Issue date: 2020 May
- ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.
- Authors: Colombo I, Zaccarelli E, Del Grande M, Tomao F, Multinu F, Betella I, Ledermann JA, Gonzalez-Martin A, Sessa C, Colombo N
- Issue date: 2020 Jul
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.
- Authors: Catanese S, Pentheroudakis G, Douillard JY, Lordick F
- Issue date: 2020 May